A FENO-BASED STRATEGY TO GUIDE ORAL CORTICOSTEROID INITIATION IN PATIENTS WITH SEVERE ASTHMA EXPERIENCING AN EXACERBATION WHILST ON TREATMENT WITH ANTI-IL5/5R THERAPY

被引：0
|
作者：
Lam, J. L. [1 ]
Hearn, A. P. [1 ]
Thomson, L. A. [1 ]
Green, L. M. [1 ]
Fernandes, M. [1 ]
Roxas, C. [1 ]
D'Ancona, G. [1 ]
Dhariwal, I. [1 ,2 ]
Nanzer, A. M. [1 ,2 ]
Jackson, D. J. [1 ,2 ]
机构：
[1] Guys & St Thomas NHS Trust, Guys Severe Asthma Ctr, London, England
[2] Kings Coll London, Sch Immunol & Microbial Sci, London, England
来源：
THORAX | 2022年 / 77卷
关键词：
D O I：
10.1136/thorax-2022-BTSabstracts.148
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
P12
引用
收藏
页码：A87 / A87
页数：1
相关论文
共 35 条
  • [1] CHANGE IN FENO AS A BIOMARKER OF RESPONSE TO ANTI-IL5/5R THERAPIES IN SEVERE ASTHMA
    Hearn, A. P.
    Kavanagh, J. E.
    Dhariwal, J.
    Nanzer, A. M.
    Jackson, D. J.
    THORAX, 2022, 77 : A80 - A80
  • [2] THE RELATIONSHIP BETWEEN FENO AND RESPONSE TO ANTI-IL5/5R BIOLOGIC THERAPIES IN SEVERE EOSINOPHILIC ASTHMA
    Hearn, A. P.
    Kavanagh, J.
    d'Ancona, G.
    Fernandes, M.
    Green, L.
    Roxas, C.
    Thomson, L.
    Dhariwal, J.
    Nanzer, A. M.
    Jackson, D. J.
    THORAX, 2021, 76 : A143 - A144
  • [3] Effectiveness of Anti-IL4R Therapy Following Suboptimal Response to Anti-IL5/5R Therapy in Severe Eosinophilic Asthma
    Mason, T.
    Hearn, A. P.
    d'Ancona, G.
    Fernandes, M.
    Green, L.
    Roxas, C.
    Thomson, L.
    Dhariwal, J.
    Nanzer, A. M.
    Jackson, D. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [4] EFFECTIVENESS OF ANTI-IL4R THERAPY FOLLOWING SUBOPTIMAL RESPONSE TO ANTI-IL5/5R THERAPY IN SEVERE EOSINOPHILIC ASTHMA
    Mason, T. W.
    Hearn, A. P.
    d'Ancona, G.
    Fernandes, M.
    Roxas, C.
    Green, L.
    Thomson, L.
    Dhariwal, J.
    Nanzer, A. M.
    Jackson, D. J.
    THORAX, 2021, 76 : A177 - A178
  • [5] Long-term effectiveness of anti-IL4R therapy following suboptimal response to anti-IL5/5R therapy in severe eosinophilic asthma
    Gates, J.
    Fernandes, M.
    Hearn, A.
    Green, L.
    Thomson, L.
    Roxas, C.
    Lam, J.
    d'Ancona, G.
    Nanzer, A. M.
    Dhariwal, J.
    Jackson, D. J.
    THORAX, 2023, 78 (SUPPL_4) : A47 - A48
  • [6] Sputum cytokines associated with raised FeNO after anti-IL5 biologic therapy in severe asthma
    Hekking, Pieter-Paul
    Zhang, Kayla
    Garrido, Carmen Paz Venegas
    Lopez-Rodriguez, Raquel
    Kjarsgaard, Melanie
    Mukherjee, Manali
    Nair, Parameswaran
    ALLERGY, 2024, 79 (08) : 2244 - 2247
  • [7] An Observation of Infection Risks in Severe Asthma Patients on Anti-IL5 Therapy
    Basirat, A.
    Maxwell, J.
    Joseph, J.
    Bradley, A.
    Moloney, E.
    Subramaniam, A.
    Lane, S.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (SUPPL 1) : S55 - S55
  • [8] Anti-IL5/IL5R Treatment in COPD: Should We Target Oral Corticosteroid-Dependent Patients?
    Laroche, Jeremy
    Pelletier, Genevieve
    Boulay, Marie-Eve
    Cote, Andreanne
    Godbout, Krystelle
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2023, 18 : 755 - 763
  • [9] Anti-IL5/IL5R switching between biologics in patients with severe eosinophilic asthma
    Yilmaz, Insu
    Cetin, Gulden Pacaci
    Arslan, Bahar
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (07): : 1935 - 1936
  • [10] Clinical Predictors of Treatment Failure to Anti-IL5 Therapy in Severe Eosinophilic Asthma
    Reihman, A. E.
    Liu, C.
    Cruse, M. H.
    Freid, L.
    Perez, N.
    Smith, V. L.
    Ferguson, L.
    Wechsler, M.
    Holguin, F.
    Manka, L.
    Sharma, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
1234